Navigation path

Note: Fields marked with * are mandatory

Myeloid U937 Skin Sensitisation Test

Topic : Skin sensitisation

Test Method Number: TM2013-02 (EU)
Short Name of TM: U-SENS™
Submission received on: June, 2013
Responsible Organisation: EURL ECVAM - European Union
Stage of Submission: Assessment Finalised
Stage of Validation: Finalised
Stage of Peer-review: Finalised
General Comments:

The U-SENS™ test method was formely called Myeloid U937 Skin Sensitisation Test (MUSST) (TM 2009-05).

Preceding TM: TM2009-05 - Myeloid U937 Skin Sensitisation Test

Method Description

The U-SENS assay supports the discrimination between sensitizing and non-sensitizing chemicals. It addresses one of the biological mechanisms described under key event 3 (events in dendritic cells (DC)) of the skin sensitization Adverse Outcome Pathway (AOP) by measuring the induction of the CD86 protein marker in U937 cells.

The U937 cells are human myeloid cells used as surrogate model for DCs. U937 is a cell line established from a diffuse histiocytic lymphoma with the advantage of higher stability and the easiness of maintenance compared to human-blood derived DCs. Although being of monocytic origin, U937 cells have shown DC-like responses following exposure to sensitizers including the up-regulation of surface marker (e.g. CD86) and cytokine production (e.g. TNF-a). The up-regulation of CD86 plays important roles in the induction of Allergic Contact Dermatitis (ACD). The CD86 protein marker is a costimulatory factor which is upregulated in...

[Read more]

Track Approval Status

  • 1
  • 2
  • 3
  • 4
  • 5
    Regulatory acceptance/Standards
CompletedSubmissionShow status
CompletedValidationShow status
CompletedPeer-reviewShow status
 Regulatory acceptance/Standards